| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA967: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over |
|
Medicine details |
|
| Medicine name | pembrolizumab (Keytruda®) |
| Formulation | intravenous infusion |
| Reference number | 3202 |
| Indication | As monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) and brentuximab vedotin (BV), or who are transplant-ineligible and have failed BV |
| Company | Merck Sharp & Dohme Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 25/05/2017 |
| NICE guidance | |